Vascular E ndothelial G rowth F actor 1 89 m RNA I soform Expression S pecifically C orrelates W ith T umor Angiogenesis, P atient S urvival, a nd P ostoperative R elapse in N on-Small-Cell L ung C ancer

Purpose: The purpose of this study was to evaluate the correlation between the expression of four different vascular endothelial growth factor (VEGF) mRNA isoforms (VEGF121, VEGF165, VEGF 189, and VEGF206) and the clinicopathologic characteristics, tumor angiogenesis, and outcome of patients with non‐small-cell lung cancer. Patients and Methods: We examined the expression of four different VEGF mRNA isoforms in 57 non‐smallcell lung cancers using reverse transcriptase polymerase chain reaction and the tumor angiogenesis using immunohistochemical staining. Results: All 57 lung cancer samples expressed the VEGF121, VEGF165, and VEGF189 mRNA isoforms, and three expressed the VEGF206 mRNA isoform. A high tumoral VEGF189 mRNA isoform expression ratio was associated with a high intratumoral microvessel count (P 5 .013), short survival (< 24 months; P 5 .001), and early postoperative relapse (< 12 months; P 5 .001). Survival and postoperative relapse time were significantly shorter in patients with a high compared with a low tumor VEGF189 mRNA isoform expression ratio (P 5 .0001 and P 5 .0086, respectively, log-rank test). In contrast, the VEGF165 and VEGF 206 mRNA isoform expression ratios showed no statistical correlation with tumor angiogenesis, postoperative relapse time, or survival. A high VEGF121 mRNA isoform expression ratio was associated with short survival (< 24 months) and early relapse (< 12 months). Multivariate analysis showed that VEGF 189 mRNA isoform expression, microvessel count, and nodal status were the most important independent prognostic factors for patient survival and postoperation recurrence. Conclusion: The VEGF189 mRNA isoform expression ratio shows a greater correlation with tumor angiogenesis, postoperative relapse time, and survival than do the expression ratios for the VEGF121, VEGF165, and VEGF206 mRNA isoforms and can be used as a prognostic indicator for patients with non‐ small-cell lung cancers. J Clin Oncol 19:432-441. © 2001 by American Society of Clinical Oncology.

[1]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.

[2]  Y. Fukushima,et al.  Aberrant isoform of vascular endothelial growth factor 189 expression is correlated with xenotransplantability of human esophageal cancer. , 1998, Oncology reports.

[3]  Y. Fukushima,et al.  Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. , 1998, International journal of oncology.

[4]  M. Volm,et al.  Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer , 1997, International journal of cancer.

[5]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[6]  L. Ellis,et al.  Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. , 1996, Cancer research.

[7]  M. Oda,et al.  Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  N. Hayashi,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. , 1996, Cancer research.

[9]  T. Sawada,et al.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma , 1996, Cancer.

[10]  Yung‐Chie Lee,et al.  Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. , 1995, American journal of respiratory and critical care medicine.

[11]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[12]  N. Weidner.  Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[13]  M. Volm,et al.  Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas. , 1995, International journal of oncology.

[14]  B Z Levi,et al.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.

[15]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[16]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[17]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[18]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[19]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[20]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[21]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[22]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[23]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[24]  D. Page,et al.  Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population , 1987, Journal of surgical oncology.

[25]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  T. Nishikawa,et al.  The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long‐term survival in Japanese patients with breast cancer , 2004, Breast Cancer Research and Treatment.

[28]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[29]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.

[30]  K. Okubo,et al.  A novel system for large-scale sequencing of cDNA by PCR amplification. , 1991, DNA sequence : the journal of DNA sequencing and mapping.

[31]  Gabriella,et al.  Advances in Brief Vascular Endothelial Growth Factor Is Associated with Neovascularization and Influences Progression of Non-Small Cell Lung Carcinoma1 , 2022 .

[32]  Y. Oshika,et al.  © 1998 Cancer Research Campaign , 2022 .